Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.69 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.63 |
| ▸ | CCR5 | P51681 | 4/20 | 0.62 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527812 | 0.83 | KCNH2 (0.55) | KCNH2GPR119CCR5PTGDR2OPRK1 | |
| SCHEMBL2404203 | 0.82 | CCR5 (0.65) | KCNH2GPR119CCR5OPRK1 | |
| Hydrochloric Acid SCHEMBL11528044 | 0.82 | KCNH2 (0.54) | KCNH2GPR119CCR5PTGDR2OPRK1 | |
| SCHEMBL2407533 | 0.82 | KCNH2 (0.49) | KCNH2GPR119CCR5 | |
| SCHEMBL2405156 | 0.82 | CCR5 (0.60) | KCNH2GPR119CCR5 | |
| SCHEMBL18388186 | 0.82 | HDAC4 (0.54) | KCNH2GPR119CCR5OPRK1 | |
| SCHEMBL13434079 | 0.80 | CCR5 (0.63) | KCNH2CCR5PTGDR2 | |
| SCHEMBL2405257 | 0.78 | CCR5 (0.62) | CCR5PTGDR2 | |
| SCHEMBL2406788 | 0.78 | CCR5 (0.62) | KCNH2GPR119CCR5 | |
| Hydrochloric Acid SCHEMBL5630464 | 0.77 | SIGMAR1 (0.71) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | KCNH2 498/4885GPR119 60/4885CCR5 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.